Form 4: Lemaitre Vascular Exec Files 10b5-1 Plan for Option Exercise
Insider Transaction Filing
A Lemaitre Vascular Senior VP filed a Form 4 detailing future stock option exercises under a Rule 10b5-1 trading plan.
Summary
- Trent G. Kamke, Senior V.P., Operations of LEMAITRE VASCULAR INC (LMAT), filed a Form 4.
- The filing reports planned transactions for January 8, 2026, under a Rule 10b5-1 trading plan.
- Kamke plans to acquire 1,229 shares of Common Stock upon exercising options at $37.29 per share.
- Additionally, Kamke plans to acquire 1,115 shares of Common Stock upon exercising options at $48.60 per share.
- Following these transactions, Kamke's direct beneficial ownership will be 5,646 shares and 6,761 shares, totaling 12,407 shares.
- Remaining derivative securities include 3,690 stock options with an exercise price of $37.29 and 5,085 stock options with an exercise price of $48.60.
Sentiment
Score: 5
Explanation: The filing reports a future, pre-scheduled exercise of stock options by an executive under a Rule 10b5-1 plan, which is a routine compensation event and does not inherently signal positive or negative company performance.
Future Outlook
This filing details future, pre-scheduled stock option exercises by a Senior VP under a Rule 10b5-1 plan, set to occur on January 8, 2026. It does not provide a general future outlook for the company.
Industry Context
This is a standard insider transaction filing, specifically detailing a pre-arranged trading plan. It does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: The filing details a pre-scheduled exercise of stock options by a Senior VP, which is a routine compensation event and does not inherently signal new information about the company's performance or strategic direction. The impact on share value from this specific filing is minimal.
Next Steps
- Execution of stock option exercises and acquisition of common stock on January 8, 2026, as per the Rule 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 12/02/2020 | Date 1,229 stock options became exercisable. |
| 12/11/2021 | Date 1,115 stock options became exercisable. |
| 01/12/2025 | Filing date of the Form 4. |
| 01/08/2026 | Transaction date for the exercise of stock options and acquisition of common stock. |
| 12/02/2027 | Expiration date for 1,229 stock options. |
| 12/11/2028 | Expiration date for 1,115 stock options. |
Recommendation
holdThis Form 4 reports a pre-scheduled exercise of stock options by an executive under a Rule 10b5-1 plan. Such transactions are routine compensation events and do not typically provide new information warranting a change in investment recommendation. Investors should consider broader company fundamentals rather than this specific insider transaction.
Keywords
LEMAITRE VASCULAR, LMAT, Form 4, Insider Transaction, Stock Options, 10b5-1 Plan, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.